Loading

SCIENCE

  • by NORML August 16, 2017

    mj_researchRepresentatives Andy Harris, M.D. (R-MD-01), Earl Blumenauer (D-OR-03), H. Morgan Griffith (R-VA-09), and Zoe Lofgren (D-CA-19) introduced H.R. 3391: The Medical Marijuana Research Act of 2017.

    This Act amends the federal law to facilitate clinical investigations involving the use of cannabis and cannabis-derived products.

    As you may know, there are many benefits to medical cannabis. Those suffering from PTSD, Tourette’s Syndrome, Parkinson’s Disease, and many other debilitating conditions have found relief because of medical marijuana.  

    But, despite the fact that over 200 million Americans now have legal access to some form of medical marijuana, present regulations make clinical investigations involving cannabis needlessly onerous. Passage of this measure would expedite federal reviews of clinical protocols, provide greater access to scientists who wish to study the drug, and mandate an FDA review of the relevant science.

    Please click HERE to contact your Representative and urge him/her to support this important measure.

     

  • by NORML August 15, 2017

    HumboldtOne of NORML’s primary missions is to move public opinion sufficiently to legalize the responsible use of marijuana by adults. One of the ways we successfully achieve this goal is by debunking marijuana myths and half-truths via the publication of timely op-eds in online and print media. Since the mainstream media seldom casts a critical eye toward many of the more over-the-top claims about cannabis, we take it upon ourselves to set the record straight.

    The majority of NORML’s rebuttals are penned by Deputy Director Paul Armentano. In the past few weeks, he has published numerous op-eds rebuking a litany of popular, but altogether specious claims about the cannabis plant – including the contentions that cannabis consumption is linked to heart attacks, psychosis, violence, and a rise in emergency room visits and traffic fatalities, among other allegations.

    Below are links to a sampling of his recent columns.:

    Blowing up the big marijuana IQ myth — The science points to zero effect on your smarts

    Blowing the lid off the ‘marijuana treatment’ racket

    The five biggest marijuana myths and how to debunk them

    It took just one distorted study for the media to freak out over health risks marijuana

    Cannabis mitigates opioid abuse — the science says so

    Three new marijuana myth-busting studies that the mainstream media isn’t picking up on

    For a broader sampling of NORML-centric columns and media hits, please visit NORML’s ‘In the Media’ archive here.

    If you see the importance of NORML’s educational and media outreach efforts, please feel free to show your support by making a contribution here.

  • by Paul Armentano, NORML Deputy Director August 10, 2017

    thumbs_upTrauma patients who test positive for marijuana upon their admission to the intensive care unit are less likely to die during hospitalization than are age-matched controls, according to data published online ahead of print in The Journal of Trauma and Acute Care Surgery.

    A team of researchers from the University of Arizona analyzed the in-hospital mortality rates of adults admitted into the ICU over a five-year period, of which 2,678 were matched (1,339: marijuana positive, 1,339 marijuana negative).

    Authors concluded: “Patients with a positive marijuana screen had a lower mortality rate (5.3 percent versus 8.9 percent) compared to patients with a negative marijuana screen. … Prospective studies with long-term follow up will be useful in answering many of the remaining questions surrounding the specific impact of marijuana on outcomes after trauma.”

    Prior studies have similarly reported greater survival rates among marijuana-positive patients hospitalized for traumatic brain injuries and heart attacks as compared to matched controls.

    An abstract of the study, “How does marijuana effect outcomes after trauma in ICU patients? A propensity matched analysis,” appears online here.

  • by Paul Armentano, NORML Deputy Director August 3, 2017

    Marijuana researchCannabis use by teens is not independently linked with adverse changes in intelligence quotient or executive functioning, according to longitudinal data published online ahead of print in the journal Addiction.

    A team of investigators from the United States and the United Kingdom evaluated whether marijuana use is directly associated with changes over time in neuropsychological performance in a nationally representative cohort of adolescent twins. Authors reported that “family background factors,” but not the use of cannabis negatively impacted adolescents’ cognitive performance.

    They wrote: “[W]e found that youth who used cannabis … had lower IQ at age 18, but there was little evidence that cannabis use was associated with IQ decline from age 12 to 18. Moreover, although cannabis use was associated with lower IQ and poorer executive functions at age 18, these associations were generally not apparent within pairs of twins from the same family, suggesting that family background factors explain why adolescents who use cannabis perform worse on IQ and executive function tests.”

    Investigators concluded, “Short-term cannabis use in adolescence does not appear to cause IQ decline or impair executive functions, even when cannabis use reaches the level of dependence.”

    Their findings are consistent with those of several other studies – including those here, here, here, and here – finding that cannabis use alone during adolescence does not appear to have a significant, direct adverse effect on intelligence quotient.

    widely publicized and still often cited New Zealand study published in 2012 in The Proceedings of the National Academy of Sciences reported that the persistent use of cannabis from adolescence to adulthood was associated with slightly lower IQ by age 38. However, a follow up review of the data published later in the same journal suggested that the observed changes were likely due to socioeconomic differences, not the subjects’ use of cannabis. A later study by the initial paper’s lead investigator further reported that the effects of persistent adolescent cannabis use on academic performance are “non-significant after controlling for persistent alcohol and tobacco use.”

  • by Justin Strekal, NORML Political Director August 2, 2017

    Per The New York Times:

    WASHINGTON — President Trump’s commission on the opioid crisis asked him Monday to declare a national emergency to deal with the epidemic.

    The members of the bipartisan panel called the request their “first and most urgent recommendation.”

    Mr. Trump created the commission in March, appointing Gov. Chris Christie of New Jersey to lead it. The panel held its first public meeting last month and was supposed to issue an interim report shortly afterward but delayed doing so until now. A final report is due in October.

    The initial recommendations are completely silent to the fact that medical marijuana access is associated with reduced rates of opioid use and abuse, opioid-related hospitalizations, opioid-related traffic fatalities, and opioid-related overdose deaths.

    Chris Christie, sitting Governor of New Jersey until Jan. 17, 2018

    Chris Christie, sitting Governor of New Jersey until Jan. 17, 2018

    Over the last two months, over 8,000 voters contacted the Office of National Drug Control Policy commission, chaired by marijuana prohibitionist Chris Christie, with their personal stories and the relevant science to encourage the group to support medical marijuana as part of the approach to reduce the tragic effects of the opioid crisis. This effort was undertaken both by NORML and Marijuana Majority.

    “Governor Christie has zero percent credibility on drug policy, or any other policy, for that matter,” Erik Altieri, Executive Director of NORML said to Forbes of Christie at the time of his appointment to head the commission.

    Nonetheless, this administration and Attorney General Jeff Sessions has continued to express skepticism with regard to the safety and efficacy of medical marijuana. Now, we now know that the President’s opioid commission is not interested in real solutions, but rather more empty rhetoric.

    We have until October until the final report is to be issued.

    Click here to send a message to the ONDCP commission to yet again tell them the facts and if you have one, please share your personal on how marijuana is a safer alternative to opioids. 

     

Page 1 of 8312345...102030...Last »